Antonio Postigo

ICREA-IDIBAPS

Grupo de investigación

Regulación génica en células madre, la plasticidad y diferenciación celular, y el cáncer Group leader (R4)

idib412@recerca.clinic.cat 0000-0003-4605-2634

Síguelo/a en:

El perfil de twitter de Antonio . Este enlace se abre en una nueva pestaña.

Publicaciones destacadas

Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation

Autores:
Martinez-Campanario, M C; Cortes, Marlies; Moreno-Lanceta, Alazne; Han, Lu; Ninfali, Chiara;

(...)

Escola-Gil, Joan C; de Frutos, Pablo Garcia; Andres, Vicente; Melgar-Lesmes, Pedro; Postigo, Antonio.

Referencia: Nature Communications 2023.
Inflammatory macrophages reprogram to immunosuppression by reducing mitochondrial translation

Autores:
Cortes, Marlies; Brischetto, Agnese; Martinez-Campanario, M C; Ninfali, Chiara; Dominguez, Veronica;

(...)

Pintado, Belen; Morales-Ruiz, Manuel; Castro, Pedro; Canete, Juan D; Postigo, Antonio.

Referencia: Nature Communications 2023.
The adaptive antioxidant response during fasting-induced muscle atrophy is oppositely regulated by ZEB1 and ZEB2

Autores:
Ninfali, Chiara; Cortes, Marlies; Martinez-Campanario, M C; Dominguez, Veronica; Han, Lu;

(...)

Esteve-Codina, Anna; Enrich, Carlos; Pintado, Belen; Garrabou, Gloria; Postigo, Antonio.

Referencia: Proceedings Of The National Academy Of Sciences Of The United States Of America 2023.
The mesodermal and myogenic specification of hESCs depend on ZEB1 and are inhibited by ZEB2

Autores:
Ninfali, Chiara; Siles, Laura; Esteve-Codina, Anna; Postigo, Antonio;

Referencia: Cell Reports 2023.
ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells

Autores:
de Barrios, Oriol; Sanchez-Moral, Lidia; Cortes, Marlies; Ninfali, Chiara; Profitos-Peleja, Nuria;

(...)

Castells, Antoni; Maurel, Joan; Salas, Azucena; Dean, Douglas C; Postigo, Antonio.

Referencia: Gut 2019.
ZEB1 protects skeletal muscle from damage and is required for its regeneration

Autores:
Siles, Laura; Ninfali, Chiara; Cortes, Marlies; Darling, Douglas S; Postigo, Antonio;

Referencia: Nature Communications 2019.
Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3

Autores:
Ninfali C; Siles L; Darling D; Postigo A;

Referencia: Nucleic Acids Research 2018.
Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells

Autores:
Liu, Yongqing; Siles, Laura; Lu, Xiaoqin; Dean, Kevin C; Cuatrecasas, Miriam;

Postigo, Antonio; Dean, Douglas C.

Referencia: Nature Communications 2018.
Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles

Autores:
Cortes, Marlies; Sanchez-Moral, Lidia; de Barrios, Oriol; Fernandez-Acenero, Maria J.; Martinez-Campanario, M. C.;

(...)

Darling, Douglas S.; Gyorffy, Balazs; Lawrence, Toby; Dean, Douglas C.; Postigo, Antonio..

Referencia: Embo Journal 2017.
ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1

Autores:
de Barrios, Oriol; Gyorffy, Balazs; Jesus Fernandez-Acenero, Maria; Sanchez-Tillo, Ester; Sanchez-Moral, Lidia;

(...)

Roue, Gael; Casal, Jose I; Darling, Douglas S; Castells, Antoni; Postigo, Antonio.

Referencia: Gut 2017.

Proyectos destacados

Cooperation and competition between colorectal carcinomas (CRC) and their tumor microenvironment: Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC.

Investigador/a principal: Antonio Postigo

Financiador: Fundació Olga Torres

Código: FUND.OLGATORRES_19_3

Duración: 01/01/2020 - 31/12/2021
Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC

Investigador/a principal: Antonio Postigo

Financiador: Asociación Española Contra el Cáncer (AECC).

Código: AECC_2019

Duración: 01/11/2019 - 31/10/2022
Validation of ZEB2 as a predictive predictive biomarker and potential therapeutic target in Duchenne muscular dystrophy

Investigador/a principal: Antonio Postigo

Financiador: Duchenne Parent Project

Código: DPP-E-2018

Duración: 16/12/2018 - 15/12/2020

Antonio Postigo

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Cooperation and competition between colorectal carcinomas (CRC) and their tumor microenvironment: Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC.

Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC

Validation of ZEB2 as a predictive predictive biomarker and potential therapeutic target in Duchenne muscular dystrophy

Suscríbete a la Newsletter del Clínic